RNA Vaccines

1 . A RNA vaccine, comprising a RNA molecule encoding for an allergen or derivative thereof, wherein the allergen is at least one allergen selected from the group consisting of Alnus glutinosa, Alternaria alternata, Ambrosia artemisiifolia, Apium graveolens, Arachis hypogaea, Betula verrucosa, Carpinus betulus, Castanea sativa, Cladosporium herbarum, Corylus avellana, Cryptomeria japonica, Cyprinus carpio, Daucus carota, Dermatophagoides pteronyssinus, Fagus sylvatica, Felis domesticus, Hevea brasiliensis, Juniperus ashei, Malus domestica, Quercus alba and Phleum pratense.

2 . The vaccine according to claim 1 , wherein the allergen is selected from the group consisting of Aln g 1, Alt a 1, Alt a 3, Alt a 4, Alt a 5, Alt a 6, Alt a 7, Alt a 8, Alt a 10, Alt a 12, Alt a 13, Amb a 1, Amb a 2, Amb a 3, Amb a 5, Amb a 6, Amb a 7, Amb a 8, Amb a 9, Amb a 10, Api g 1, Api g 4, Api g 5, Ara h 1, Ara h 2, Ara h 3, Ara h 4, Ara h 5, Ara h 6, Ara h 7, Ara h 8, Bet v 1, Bet v 2, Bet v 3, Bet v 4, Bet v 6, Bet v 7, Car b 1, Cas s 1, Cas s 5, Cas s 8, Cla h 2, Cla h 5, Cla h 6, Cla h 7, Cla h 8, Cla h 9, Cla h 10, Cla h 12, Cor a 1, Cor a 2, Cor a 8, Cor a 9, Cor a 10, Cor a 11, Cry j 1, Cry j 2, Cyp c 1, Dau c 1, Dau c 4, Der p 1, Der p 2, Der p 3, Der p 4, Der p 5, Der p 6, Der p 7, Der p 8, Der p 9, Der p 10, Der p 11, Der p 14, Der p 20, Der p 21, Clone 30 allergen, Fag s 1, Fel d 1, Fel d 2, Fel d 3, Fel d 4, Fel d 5w, Fel d 6w, Fel d 7w, Hev b 1, Hev b 2, Hev b 3, Hev b 4, Hev b 5, Hev b 6.01, Hev b 6.02, Hev b 6.03, Hev b 7.01, Hev b 7.02, Hev b 8, Hev b 9, Hev b 10, Hev b 11, Hev b 12, Hev b 13, Jun a 1, Jun a 2, Jun a 3, Mal d 1, Mal d 2, Mal d 3, Mal d 4, Que a 1, Phl p 1, Phl p 2, Phl p 4, Phl p 5, Phl p 6, Phl p 7, Phl p 11, Phl p 12 and Phl p 13.

3 . The vaccine according to claim 1 , characterised in that wherein the allergen is selected from the group consisting of Aln g 1, Alt a 1, Amb a 1, Api g 1, Ara h 2, Bet v 1, beta-casein, Car b 1, Cas s 1, Cla h 8, Cor a 1, Cry j 1, Cyp c 1, Dau c 1, Der p 2, Fag s 1, Fel d 1, Hev b 6, Jun a 1, Mal d 1, ovalbumin (OVA), Phl p 1, Phl p 2, Phl p 5, Phl p 6 and Phl p 7.

4 . The vaccine according to claim 1 , wherein the allergen is selected from the group consisting of Phl p 1, Phl p 2, Phl p 5 Phl p6, Aln g 1, Cor a 1, Que a 1, Car b 1 and Bet v 1.

5 . The vaccine according to claim 1 , wherein the allergen derivative is hypoallergenic.

6 . The vaccine according to claim 5 , wherein the hypoallergenic allergen derivative exhibits an IgE reactivity which is at least 10% lower than the IgE reactivity of the wild-type allergen.

7 . The vaccine according to claim 1 , wherein the RNA molecule encoding the allergen or derivative thereof is fused to a further molecule encoding a peptide, polypeptide or protein.

8 . The vaccine according to claim 1 , wherein the RNA molecule comprises at least one further element selected from the group consisting of replicase, 1-globin leader sequence, cap0, cap1 and poly A tail.

9 . The vaccine according to claim 1 , further comprising a CpG-DNA adjuvant.

10 . The vaccine according to claim 1 , wherein the vaccine is adapted for intramuscular, intradermal, intravenous, transdermal, topical or biolistic administration.

11 . A method for treating or preventing allergy, comprising administering the RNA vaccine according to claim 1 into a body or into cells outside of the body.

12 . A method for manufacturing a protective and therapeutic vaccine for hyposensitising an individual to an allergen, comprising employing a RNA molecule encoding for an allergen or derivative thereof, to obtain the RNA vaccine according to claim 1 .

13 . The method according to claim 11 , wherein the vaccine further comprises an adjuvant selected from the group consisting of CpG-DNA and cytokines.

14 . The method according to claim 11 , wherein the vaccine is adapted for intramuscular, intradermal, intravenous, transdermal, topical or biolistic administration.

15 . An isolated RNA molecule comprising a nucleotide sequence encoding an allergen or derivative thereof as defined in claim 1 .

16 . The method according to claim 12 , wherein the vaccine further comprises an adjuvant selected from the group consisting of CpG-dNA and cytokines.

17 . The method according to claim 12 , wherein the vaccine is adapted for intramuscular, intradermal, intravenous, transdermal, topical or biolistic administration.

18 . The vaccine according to claim 1 , further comprising a cytokine adjuvant.

19 . The vaccine according to claim 18 , wherein the cytokine adjuvant is at least one selected from the group consisting of IL-12 and IL-15.